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Rita Jacobs, Patrick M Honore* and Herbert D SpapenPlease see related research by Schilder et al. http://ccforum.com/content/18/4/472 and related commentary by Oudemans-van Straaten
http://ccforum.com/content/18/6/661We read with great interest the paper by Schilder and
colleagues on citrate anticoagulation versus systemic
heparinisation (CASH) [1] and its related commentary
[2], but would like to comment on two important meta-
bolic issues.
First, in-circuit ionized calcium was not monitored in
the CASH trial. Keeping postfilter ionized calcium within
tight limits, however, results in more optimal anticoagula-
tion, improves filter lifespan, and better regulates buffer
supply. When studying this approach, we obtained a lon-
ger median filter survival time than that in the CASH
study (98.4 versus 46 hours) [3]. We also infused calcium
through a dedicated central venous line. As a result, the
remaining citrate was not deactivated and its reinjection
allowed continuous flushing of the dialysis catheter [3].
Second, in the presence of similar citrate and chloride
flows, only a 2% incidence of metabolic alkalosis was ob-
served in the regional citrate anticoagulation arm of the
CASH trial whereas it occurred in all of our study pa-
tients after 48 hours [3]. In fact, an overly simplified def-
inition of metabolic alkalosis (pH >7.5) was used in the
CASH study [1]. Applying pH cutoff values of 7.5 and
7.45 identified metabolic alkalosis only in <1% and 12%
of our study population, respectively [4]. We used the
Stewart equation for evaluating the interacting impact of
citrate, chloride, bicarbonate buffer and respiratory (over)
compensation on acid–base status [5].
When calculating strong ion differences for patients
receiving regional citrate anticoagulation in the CASH
protocol, in particular at higher blood flow and thus
higher citrate substitution, a substantially higher inci-
dence of metabolic alkalosis would be noticed.* Correspondence: Patrick.Honore@uzbrussel.be
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